Fasenra Approved for New Use in India

  Published 10 months ago

AstraZeneca’s Fasenra (Benralizumab) has received Indian regulatory approval for an additional indication: treating adult patients with relapsing or refractory eosinophilic granulomatosis with polyangiitis (EGPA). Marketing is pending further statutory approvals.

  • Fasenra gets expanded use in India.
  • Treats EGPA in adult patients.
  • Approval from Indian regulators.

You might like these

Global Science Race: US Funding Cuts Spur Talent Grab

Global Markets Mixed: Trade Tensions & Oil Rise

July 2025 CPI Rise for Indian Labourers

GPPL Eyes Major Port Expansion

Bhagyanagar India Soars on Q1 Profit

SAIL & ABB Partner for Digital Steel Plant

Indian Two-Wheeler Stocks Dip on New ABS Rule Outlook

News that matters the most ⚡